Lung Cancer

Tagrisso plus Orpathys improved progression-free survival in patients with EGFR-mutated lung cancer and MET overexpression, SANOVO trial shows.

Researchers are studying how genetics and environmental factors may influence lung cancer risk and could help shape the future of screening and treatment.

Nicole Echols discusses Lung Cancer Initiative, reducing lung cancer stigma, biomarker testing, early detection and support for patients and caregivers.

Dr. Jia Luo explains how chemotherapy, targeted therapy and immunotherapy work for lung cancer, plus tips for managing treatment side effects.

The phase 3 DESTINY-Lung04 trial met its main goal of keeping cancer from growing longer than chemotherapy plus immunotherapy did.

At least half of patients get nervous before a follow-up scan. Dr. Geoffrey Pelz explains why that is common, what he wants patients to hear at the first visit and how much lung cancer treatment has shifted in 15 years.

After receiving a Stage 1 lung cancer diagnosis, Carolyn Rothfeld underwent robotic surgery to remove part of her lung and is back to her exercise routine nine months later.

Biomarker testing looks for genes, proteins and other markers in your cancer that can help your care team choose the most effective treatment for you.

As Canadian wildfire smoke blankets much of the U.S., here's what people with cancer and cancer survivors should know about the potential health risks.

After reaching remission from stage 3B non-small cell lung cancer, one survivor shares the emotional journey of healing, hope and finding a new normal.

Join LiveLung's Charlotte meeting to learn how The White Ribbon Project is raising lung cancer awareness, reducing stigma and supporting patients.

AURORA, a phase 3 trial, is testing aglatimagene besadenovec plus Keytruda in patients with lung cancer who progressed on immunotherapy.

A kidney cancer survivor reflects on National Doctors Day and how trust with his oncologist, Dr. Toni Choueiri, became a lifelong bond.

Investigational bispecific antibody pumitamig achieved a 70% response rate and disease control in all evaluable patients with advanced NSCLC.

ASCO 2026 highlighted advances in pancreatic, breast, sarcoma, lung and prostate cancers that may reshape treatment.

Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy.

Study data shows Ibtrozi provides rapid symptom relief and stable brain health for patients with advanced ROS1-positive lung cancer.

Patients with EGFR exon 20-positive NSCLC had longer progression-free survival with Zegfrovy than chemotherapy.

ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.

A lung and breast cancer survivor shares how genetic history, supporting her daughter and leading a support group helped her keep smiling.

A SEER-Medicare study found nearly half of older patients with metastatic non–small cell lung cancer never received systemic therapy.

New therapies are beginning to crack KRAS, offering tumor shrinkage and longer survival as researchers work to overcome resistance.

New T-cell engagers and ADCs show survival gains in pretreated small cell lung cancer, signaling long-awaited progress and more treatment options for patients.

Dietitian Stephanie Meyers shared practical strategies at the LiveLung SCLC Patient Summit to help patients manage appetite loss and digestive issues.

A man with small cell lung cancer describes carboplatin-related hearing loss, fatigue and daily challenges that have reshaped his life, while holding onto perspective and resilience.